BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Atanasov G, Hau HM, Dietel C, Benzing C, Krenzien F, Brandl A, Wiltberger G, Matia I, Prager I, Schierle K. Prognostic significance of macrophage invasion in hilar cholangiocarcinoma. BMC Cancer. 2015;15:790. [PMID: 26497197 DOI: 10.1186/s12885-015-1795-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Uson Junior PLS, Araujo RL. Immunotherapy in biliary tract cancers: Current evidence and future perspectives. World J Gastrointest Oncol 2022; 14(8): 1446-1455 [DOI: 10.4251/wjgo.v14.i8.1446] [Reference Citation Analysis]
2 Param NJ, Bramel ER, Sia D. The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.05.006] [Reference Citation Analysis]
3 Guo H, Qian Y, Yu Y, Bi Y, Jiao J, Jiang H, Yu C, Wu H, Shi Y, Kong X. An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. Front Oncol 2022;12:791867. [DOI: 10.3389/fonc.2022.791867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, Pereira SP, Rengo M, Kather JN, Lamarca A, Pedica F, Forner A, Valle JW, Gaudio E, Alvaro D, Banales JM, Carpino G. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 2022:gutjnl-2022-327099. [PMID: 35580963 DOI: 10.1136/gutjnl-2022-327099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu Z, Chen W, Wang Z, Liu X, Fan H, Xu L, Pan Y, Zhong S, Xie D, Bai J, Jiang Y, Zhang Y, Dai H, Chen Z. Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study. Front Oncol 2022;12:849053. [DOI: 10.3389/fonc.2022.849053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chen S, Chen Z, Li Z, Li S, Wen Z, Cao L, Chen Y, Xue P, Li H, Zhang D. Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256. Cell Death Dis 2022;13:94. [PMID: 35091535 DOI: 10.1038/s41419-022-04534-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
7 Zhou M, Wang C, Lu S, Xu Y, Li Z, Jiang H, Ma Y. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine 2021;67:103375. [PMID: 33993051 DOI: 10.1016/j.ebiom.2021.103375] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
8 Schoenberg MB, Li X, Li X, Han Y, Hao J, Miksch RC, Koch D, Börner N, Beger NT, Bucher JN, Schiergens TS, Guba MO, Werner J, Bazhin AV. The predictive value of tumor infiltrating leukocytes in Hepatocellular Carcinoma: A systematic review and meta-analysis. Eur J Surg Oncol 2021:S0748-7983(21)00473-X. [PMID: 33966947 DOI: 10.1016/j.ejso.2021.04.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Casolino R, Braconi C. CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma. J Hepatol 2021;74:1021-4. [PMID: 33612309 DOI: 10.1016/j.jhep.2021.01.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Soares KC, Jarnagin WR. The Landmark Series: Hilar Cholangiocarcinoma. Ann Surg Oncol 2021;28:4158-70. [PMID: 33829358 DOI: 10.1245/s10434-021-09871-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
11 Smolle MA, Herbsthofer L, Goda M, Granegger B, Brcic I, Bergovec M, Scheipl S, Prietl B, El-Heliebi A, Pichler M, Gerger A, Posch F, Tomberger M, López-García P, Feichtinger J, Baumgartner C, Leithner A, Liegl-Atzwanger B, Szkandera J. Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma. Oncoimmunology 2021;10:1896658. [PMID: 33763294 DOI: 10.1080/2162402X.2021.1896658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Ueno M, Ikeda M, Sasaki T, Nagashima F, Mizuno N, Shimizu S, Ikezawa H, Hayata N, Nakajima R, Morizane C. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer 2020;20:1105. [PMID: 33198671 DOI: 10.1186/s12885-020-07365-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
13 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 548] [Cited by in F6Publishing: 583] [Article Influence: 274.0] [Reference Citation Analysis]
14 Loeuillard E, Conboy CB, Gores GJ, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep. 2019;1:297-311. [PMID: 32039381 DOI: 10.1016/j.jhepr.2019.06.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 14.7] [Reference Citation Analysis]
15 Chang TT, Tsai HW, Ho CH. Fucosyl-Agalactosyl IgG₁ Induces Cholangiocarcinoma Metastasis and Early Recurrence by Activating Tumor-Associated Macrophage. Cancers (Basel) 2018;10:E460. [PMID: 30469416 DOI: 10.3390/cancers10110460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Chen Z, Guo P, Xie X, Yu H, Wang Y, Chen G. The role of tumour microenvironment: a new vision for cholangiocarcinoma. J Cell Mol Med. 2019;23:59-69. [PMID: 30394682 DOI: 10.1111/jcmm.13953] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
17 Gentilini A, Pastore M, Marra F, Raggi C. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium. Int J Mol Sci. 2018;19. [PMID: 30249019 DOI: 10.3390/ijms19102885] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
18 Yang M, McKay D, Pollard JW, Lewis CE. Diverse Functions of Macrophages in Different Tumor Microenvironments. Cancer Res 2018;78:5492-503. [PMID: 30206177 DOI: 10.1158/0008-5472.CAN-18-1367] [Cited by in Crossref: 221] [Cited by in F6Publishing: 234] [Article Influence: 55.3] [Reference Citation Analysis]
19 Atanasov G, Dietel C, Feldbrügge L, Benzing C, Krenzien F, Brandl A, Katou S, Schierle K, Robson SC, Splith K, Wiltberger G, Reutzel-Selke A, Jonas S, Pascher A, Bahra M, Pratschke J, Schmelzle M. Angiogenic miRNAs, the angiopoietin axis and related TIE2-expressing monocytes affect outcomes in cholangiocarcinoma. Oncotarget 2018;9:29921-33. [PMID: 30042823 DOI: 10.18632/oncotarget.25699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
20 Atanasov G, Pötner C, Aust G, Schierle K, Dietel C, Benzing C, Krenzien F, Bartels M, Eichfeld U, Schmelzle M, Bahra M, Pascher A, Wiltberger G. TIE2-expressing monocytes and M2-polarized macrophages impact survival and correlate with angiogenesis in adenocarcinoma of the pancreas. Oncotarget 2018;9:29715-26. [PMID: 30038715 DOI: 10.18632/oncotarget.25690] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
21 Saengboonmee C, Sawanyawisuth K, Chamgramol Y, Wongkham S. Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Expert Rev Anticancer Ther 2018;18:579-92. [PMID: 29676221 DOI: 10.1080/14737140.2018.1467760] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
22 Minami K, Hiwatashi K, Ueno S, Sakoda M, Iino S, Okumura H, Hashiguchi M, Kawasaki Y, Kurahara H, Mataki Y, Maemura K, Shinchi H, Natsugoe S. Prognostic significance of CD68, CD163 and Folate receptor-β positive macrophages in hepatocellular carcinoma. Exp Ther Med 2018;15:4465-76. [PMID: 29731831 DOI: 10.3892/etm.2018.5959] [Cited by in Crossref: 17] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
23 Xu B, Chen L, Li J, Zheng X, Shi L, Wu C, Jiang J. Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients. Oncotarget. 2016;7:74904-74916. [PMID: 27736796 DOI: 10.18632/oncotarget.12484] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
24 Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2018;1864:1435-43. [PMID: 28757170 DOI: 10.1016/j.bbadis.2017.07.028] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
25 Atanasov G, Dietel C, Feldbrügge L, Benzing C, Krenzien F, Brandl A, Mann E, Englisch JP, Schierle K, Robson SC, Splith K, Morgul MH, Reutzel-Selke A, Jonas S, Pascher A, Bahra M, Pratschke J, Schmelzle M. Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma. Oncoimmunology 2017;6:e1331806. [PMID: 28919993 DOI: 10.1080/2162402X.2017.1331806] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
26 Tashireva LA, Perelmuter VM, Manskikh VN, Denisov EV, Savelieva OE, Kaygorodova EV, Zavyalova MV. Types of Immune-Inflammatory Responses as a Reflection of Cell-Cell Interactions under Conditions of Tissue Regeneration and Tumor Growth. Biochemistry (Mosc) 2017;82:542-55. [PMID: 28601064 DOI: 10.1134/S0006297917050029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
27 Ren CX, Leng RX, Fan YG, Pan HF, Li BZ, Wu CH, Wu Q, Wang NN, Xiong QR, Geng XP, Ye DQ. Intratumoral and peritumoral expression of CD68 and CD206 in hepatocellular carcinoma and their prognostic value. Oncol Rep 2017;38:886-98. [PMID: 28656201 DOI: 10.3892/or.2017.5738] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
28 Feng D, Xiong Y, Peng Z, Ma Q, Tao T, Liu H, Liang J, Wei Z, Zheng J, Wang L, Zhang H. Reduced EBP50 expression levels are correlated with unfavorable clinicopathological features of extrahepatic bile duct carcinoma and promote the proliferation and migration of QBC939 cells. Oncol Lett 2017;13:2758-64. [PMID: 28454463 DOI: 10.3892/ol.2017.5789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Brivio S, Cadamuro M, Strazzabosco M, Fabris L. Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. World J Hepatol 2017; 9(9): 455-468 [PMID: 28396716 DOI: 10.4254/wjh.v9.i9.455] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
30 Atanasov G, Schierle K, Hau HM, Dietel C, Krenzien F, Brandl A, Wiltberger G, Englisch JP, Robson SC, Reutzel-Selke A, Pascher A, Jonas S, Pratschke J, Benzing C, Schmelzle M. Prognostic Significance of Tumor Necrosis in Hilar Cholangiocarcinoma. Ann Surg Oncol 2017;24:518-25. [PMID: 27480355 DOI: 10.1245/s10434-016-5472-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
31 Atanasov G, Hau H, Dietel C, Benzing C, Krenzien F, Brandl A, Englisch JP, Wiltberger G, Schierle K, Robson SC, Reutzel-selke A, Jonas S, Pascher A, Pratschke J, Schmelzle M. Prognostic significance of TIE2-expressing monocytes in hilar cholangiocarcinoma: TEMs in Cholangiocarcinoma. J Surg Oncol 2016;114:91-8. [DOI: 10.1002/jso.24249] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
32 Dong P, Ma L, Liu L, Zhao G, Zhang S, Dong L, Xue R, Chen S. CD86⁺/CD206⁺, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis. Int J Mol Sci 2016;17:320. [PMID: 26938527 DOI: 10.3390/ijms17030320] [Cited by in Crossref: 81] [Cited by in F6Publishing: 96] [Article Influence: 13.5] [Reference Citation Analysis]
33 Hoffmann K, Schemmer P, Büchler MW. Reply to: "Impact of portal vein resection on oncologic long-term outcome in patients with hilar cholangiocarcinoma". Surgery 2016;159:987-8. [PMID: 26791270 DOI: 10.1016/j.surg.2015.11.023] [Reference Citation Analysis]